Regeneron To Stop Giving Placebo In COVID-19 Antibody Trial After 'Clear Efficacy'

• Following recommendations from the Independent Data Monitoring Committee (IDMC), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) will make changes to the Phase 3 trial evaluating REGEN-COV (casirivimab with imdevimab) in outpatients with COVID-19.

• The company said that an independent panel found the company's COVID-19 antibody cocktail at both 1,200mg and 2,400mg doses have "clear clinical efficacy" in reducing the rates of hospitalization and deaths in patients.

• The panel has recommended that Regeneron should stop enrolling patients in the placebo group.

• The cocktail was authorized in November for emergency use by the FDA.

• The company plans to share details of unblinded data from the trial once it becomes available in March.

• Price Action: REGN is marginally up by 0.5% at $460.9 in premarket trading on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies

• Opthea Outlines OPT-302 Pivotal Study Designs In Chronic Eye Disorder

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.